

## Special Issue

# The Gut Microbiome as a Target for the Treatment of Inflammatory Bowel Diseases

### Message from the Guest Editors

Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, are chronic and debilitating disorders characterized by chronic inflammation of the gastrointestinal tract. For a long time, these conditions were primarily viewed as immune-mediated disorders with genetic and environmental factors playing key roles. The exploration of the gut microbiome's role as a target for the treatment of inflammatory bowel diseases (IBDs) is a dynamic and rapidly evolving field that has gained significant attention over the past couple of decades. The topic continues to drive innovative research with the potential to revolutionize our understanding of IBD pathogenesis and treatment approaches. The aim of this Special Issue is to present cutting-edge research and advancements in understanding the pivotal role of the gut microbiome in the treatment of inflammatory bowel diseases (IBDs). By assembling a collection of multidisciplinary research, we aim to provide a comprehensive overview of the potential therapeutic opportunities offered by harnessing the gut microbiome's intricate interactions with the host immune system.

---

### Guest Editors

Dr. Limin Shi

Medicine-Endocrinology and Metabolism Department, School of Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA

Dr. Zhipeng Tao

Department of Nutrition and Food Sciences, Texas Woman's University, Denton, TX 76209, USA

---

### Deadline for manuscript submissions

closed (25 May 2025)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/181684](https://mdpi.com/si/181684)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://www.mdpi.com)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).